share_log

Craig-Hallum Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Cuts Target Price to $12

Moomoo News ·  Nov 8 23:30  · Ratings

Craig-Hallum analyst Matt Hewitt maintains $Maravai LifeSciences (MRVI.US)$ with a buy rating, and adjusts the target price from $15 to $12.

According to TipRanks data, the analyst has a success rate of 44.6% and a total average return of -0.5% over the past year.

AnalystRecentRatingAutoNews_79796197611528_20241108_00946829d6ea2a732931ad35d725101cb47f1a27_1731079801099705_mm_en

Furthermore, according to the comprehensive report, the opinions of $Maravai LifeSciences (MRVI.US)$'s main analysts recently are as follows:

  • Following three consecutive quarters of strong performance in comparison to their forecasts, Maravai Lifesciences experienced a setback due to the challenging biotech spending climate and the irregular ordering patterns from customers that are characteristic of their industry.

  • Maravai Lifesciences' third-quarter results fell short of expectations, with performance in both segments not meeting projections. The company indicated a decline in research/discovery demand, an absence of sizable drop-in orders, and some delays in GMP program timing extending into 2025.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment